SCHEMBL4216013

SCHEMBL4216013

NNC(=O)CCC1=CCOc2cc(OCc3cccc(F)c3)ccc21

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MAOB P27338 14/20 0.52
GRM5 P41594 1/20 0.52
PARP10 Q53GL7 1/20 0.44
NR4A2 P43354 2/20 0.43
MAOA P21397 5/20 0.42
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4208317 0.91 MAOB (0.52) MAOBGRM5PARP10NR4A2MAOA
SCHEMBL4208110 0.91 MAOB (0.54) MAOBGRM5PARP10NR4A2MAOA
SCHEMBL4209941 0.90 MAOB (0.55) MAOBGRM5PARP10NR4A2MAOA
SCHEMBL4206480 0.89 MAOB (0.50) MAOBGRM5MAOANPC1LMNA
SCHEMBL4219782 0.84 MAOB (0.57) MAOBGRM5PARP10MAOA
SCHEMBL4211558 0.84 MAOB (0.57) MAOBGRM5PARP10NR4A2MAOA
SCHEMBL4206386 0.83 MAOB (0.54) MAOBGRM5PARP10NR4A2MAOA
SCHEMBL4213101 0.80 MAOB (0.50) MAOBGRM5MAOANPC1HPGD
SCHEMBL4224787 0.79 MAOB (0.52) MAOBGRM5MAOANPC1LMNA
SCHEMBL4217653 0.79 MAOB (0.54) MAOBGRM5PARP10NR4A2MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1863784-A1 SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES Newron Pharmaceuticals S.p.A. (IT) 2007-12-12 EP claimed
WO-2006102958-A1 SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES NEWRON PHARMACEUTICALS S.P.A. (IT) 2006-10-05 WO claimed
US-20090005436-A1 Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives NEWRON PHARMACEUTICALS S.P.A. (IT) 2009-01-01 US disclosed
EP-1863784-A1 SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES Newron Pharmaceuticals S.p.A. (IT) 2007-12-12 EP disclosed
WO-2006102958-A1 SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES NEWRON PHARMACEUTICALS S.P.A. (IT) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005436-A1 Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives MAOB, MAOA, AOC3 MAOB 1/4885GRM5 1809/4885PARP10 450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.